An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Trial Profile

An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2018

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications Adenovirus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms AdAPT; Study 999
  • Sponsors Chimerix
  • Most Recent Events

    • 08 Aug 2018 According to a Chimerix media release, this study is open for enrollment in the United States (US), the United Kingdom (UK), and Europe. Four of nine planned countries are currently undergoing regulatory or central ethics review; additional sites in the US, UK and Europe are also in the process of opening for enrollment.
    • 07 May 2018 According to a Chimerix media release, the company is focusing on execution of this 141-patient trial and anticipate data read-out in the second half of 2019.
    • 01 Mar 2018 According to a Chimerix media release, data expected in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top